Study design (if review, criteria of inclusion for studies)
Randomized double-blind placebo-controlled study design with an iso-nitrogenous placebo.
Participants
39 Cystic fibrosis adults patients
Interventions
Glutamine supplementation (21 g/day) for 8 weeks or iso-nitrogenous placebo.
Outcome measures
The primary analysis was intention to treat, and the primary outcome was change in induced sputum neutrophils.
Main results
Thirty-nine individuals were recruited and thirty-six completed the study. Glutamine supplementation had no impact on any of the outcome measures in the intention-to-treat analysis. In the per protocol analysis, glutamine supplementation was associated with an increase in induced sputum neutrophils (P = 0.046), total cells (P = 0.03), and in Pseudomonas isolation agar colony forming units (P = 0.04) compared to placebo.
Authors' conclusions
There was no effect of glutamine supplementation on markers of pulmonary inflammation in the intention-to-treat analysis.